Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s. Some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market, while Novo works to turn itself around. The competitive dynamics in the GLP-1 space are shifting, with Lilly's momentum posing a challenge to Novo's market leadership.